Teva CORE | Comprehensive Oncology Reimbursement Expertise
Teva CORE | Comprehensive Oncology Reimbursement Expertise
Kåre Schultz forlænger kontrakt med Teva — MedWatch
Teva USA
Teva tæt på målet i amerikansk opioid-forlig — MedWatch
Teva CEO Kåre Schultz discusses company's latest quarter and opioid settlement - YouTube
Kåre Schultz får lønforhøjelse på 26 mio. kr. — MedWatch
Teva indgår milliardforlig i opiodsag — MedWatch
Kåre Schultz på vej væk fra Teva Pharmaceutical | www.euroinvestor.dk Nyheder - www.euroinvestor.dk
Cureatr to Be Named Top Place to Work for Work Flexibility and Vacation and Time off in Muse Vibe Awards 2022
Now That Teva Has Stabilized, Teva Stock Looks Undervalued | InvestorPlace
Teva takes 2nd long-acting schizophrenia drug into phase 3
Dansk topchef stopper i Teva før tid
Ex-pharmaceutical company boss faces insider trading charges over Teva deal | The Times of Israel
Kåre Schultz venter at stoppe i Teva i 2023 — MedWatch
Teva CEO Schultz took a big pay cut last year—but he bagged a contract extension, too | Fierce Pharma
Kåre Schultz er tavs om mulig kontraktforlængelse: “Det skaber bare unødvendige rygter”
Teva: Er det nu Kåre? | Nordnet
Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis® in the United States | Business Wire
Teva CORE | Comprehensive Oncology Reimbursement Expertise
Business-update: Kåre Schultz forgyldt med lønforhøjelse på op til 26 mio. kroner
Teva taps new CFO, hikes legal set-aside to more than $1B as opioid deal falters | Fierce Pharma
Teva to expand into long-acting Schizophrenia injectable medication - LifeSci Voice
Kåre Schultz forlænger kontrakt med Teva — MedWatch
